TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Condition:   Hormone Receptor Positive HER-2 Negative Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide Sponsor:   Fudan University Not yet recruiting

Source: ClinicalTrials.gov - June 13, 2023 Category: Research Source Type: clinical trials